Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development of the former’s ...

Apremilast improves disease severity and patient-reported outcomes among adults with psoriasis, regardless of genital involvement.

"We are excited to initiate the Phase 3 study and we believe that Piclidenoson's oral dosage and excellent safety record, ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

LEO Pharma and Reig Jofre have entered into a partnership aimed at improving access to LEO’s psoriasis treatment in Europe.

The study will enroll patients with moderate to severe plaque psoriasis. Patient enrolment will be initiated in Europe and US and Canada expected to follow. The study is a randomized, double-blind ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) ...

STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...

Bio-Thera and Dr. Reddy's partner for biosimilar commercialization in Southeast Asia, expanding access to affordable ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...